Exchange Traded Concepts LLC Acquires New Shares in CRISPR Therapeutics AG $CRSP

Exchange Traded Concepts LLC acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 18,555 shares of the company’s stock, valued at approximately $903,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in CRSP. Deutsche Bank AG lifted its position in shares of CRISPR Therapeutics by 65.0% in the fourth quarter. Deutsche Bank AG now owns 8,133 shares of the company’s stock worth $320,000 after buying an additional 3,205 shares during the last quarter. Two Sigma Advisers LP lifted its position in shares of CRISPR Therapeutics by 50.4% in the fourth quarter. Two Sigma Advisers LP now owns 84,800 shares of the company’s stock worth $3,338,000 after buying an additional 28,400 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of CRISPR Therapeutics by 2.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 690,191 shares of the company’s stock worth $27,166,000 after buying an additional 13,865 shares during the last quarter. Sunbelt Securities Inc. increased its stake in shares of CRISPR Therapeutics by 108.6% in the fourth quarter. Sunbelt Securities Inc. now owns 6,165 shares of the company’s stock worth $238,000 after purchasing an additional 3,210 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in shares of CRISPR Therapeutics in the fourth quarter worth about $71,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CRSP. Barclays lifted their price objective on CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Chardan Capital reiterated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, August 5th. Royal Bank Of Canada lifted their price objective on CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a “sector perform” rating in a research note on Tuesday, August 5th. Zacks Research upgraded CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $81.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, July 8th. Ten equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, CRISPR Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $71.50.

CRISPR Therapeutics Trading Down 2.2%

CRSP stock opened at $60.76 on Wednesday. The firm has a market cap of $5.53 billion, a P/E ratio of -11.19 and a beta of 1.81. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $71.13. The business’s 50 day moving average is $57.43 and its 200-day moving average is $46.56.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, August 4th. The company reported ($1.29) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.18. The business had revenue of $0.89 million for the quarter, compared to the consensus estimate of $6.44 million. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.CRISPR Therapeutics’s revenue was up 72.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.49) EPS. Sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, Director Simeon George bought 989,812 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, July 16th. The shares were acquired at an average cost of $52.03 per share, with a total value of $51,499,918.36. Following the acquisition, the director directly owned 1,730,179 shares of the company’s stock, valued at $90,021,213.37. The trade was a 133.69% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.